Veru reports q4 loss per share $0.05

Veru reports fiscal 2019 full-year net revenues doubled, gross profit up 147%.q4 loss per share $0.05.q4 revenue $8.7 million versus refinitiv ibes estimate of $9.2 million.q4 earnings per share estimate $-0.05 -- refinitiv ibes data.advancing veru-111 into three phase 2 clinical studies in additional cancer types.veru-111 appears to be well tolerated with a wide safety margin.veru-111 has signs of antitumor activity and an acceptable safety profile.veru-111 has promising signs of progression free survival.plan to submit ind application for veru-100 in early 2020.company believes that it has sufficient resources to execute clinical drug trial programs through year end 2021.
VERU Ratings Summary
VERU Quant Ranking